ABT

150-Page Report Forecasts Market Growth from $8.50B (2025) to $18.50B by 2034, Profiling Roche, Abbott, Siemens Healthineers, Thermo Fisher, Labcorp, and 5 Other Key PlayersDublin, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The "Blood Based Biomarkers - Market Insights, Competitive Landscape, and Market Forecast - 2034" has been added to ResearchAndMarkets.com's offering.

Medtronic's outlook looks better with stronger growth and earnings, but margin, currency, and execution risks keep investors cautious. The company remains selective for those weighing potential upside against lingering uncertainties.

Boston Scientific's 2026 growth outlook has weakened due to pressure on its WATCHMAN and EP products. However, seven new launches and planned cost savings could help the company recover by 2028.

Abbott, the global healthcare leader, announced today it has received U.S. Food and Drug Administration (FDA) approval for the TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ to treat patients with challenging cases of atrial fibrillation (AFib). The U.S.

TD Cowen continues to recommend Abbott Laboratories, maintaining a $135 price target. The analyst sees the company as a solid investment opportunity.

A dividend‑heavy stock with a 54‑year payout streak may appeal to investors worried about a market downturn. The company’s long record and potential catalysts could offer income even in a pullback.

The FDA has approved Abbott’s TactiFlex Duo Ablation Catheter, a sensor‑enabled device that combines pulsed field and radiofrequency energy. It is designed to treat complex atrial fibrillation cases.

Report Features In-Depth Profiles of Abbott, Great Robotics, Intuitive Surgical, Johnson & Johnson, Medtronic, Panasonic, Renishaw, Siemens Healthineers, Smith+Nephew, Stryker, Zimmer Biomet, and FreehandDublin, Sept.